BRAF and melanoma: Of the patients with melanoma, 125 (61.9%) were treatment‐naïve, 78 (38.6%) had an elevated LDH at commencement of immunotherapy, 39 (19.3%) were BRAF V600E positive, 150 (74.3%) were Stage VI M1C/D by the AJCC Melanoma Staging 8th Edition.22